LEADERSHIP TEAM
MANAGEMENT TEAM
Our experienced executive team is committed to finding innovative solutions for patients living with infectious diseases, cancer, and monogenic disorders.
Jeffrey A. Galvin
CEO and
Founder
Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.
C. David Pauza, PhD
Chief Science
Officer
David has 35 years of experience in HIV, immunology, virology, and cancer biology, and has held faculty positions and at University of Wisconsin and University of Maryland medical schools. Prior to joining AGT, David was Adjunct Professor of Medicine at the University of Maryland Medical School in Baltimore.
C. Neil Lyons, CPA
Chief Financial Officer & Executive Vice President
Neil has more than 30 years of experience in finance, strategy, raising capital, SEC compliance, and corporate governance in both public and private companies, with over 10 years of that leading finance for publicly-traded, clinical-stage biotechnology companies.
Irene Tennant
Director,
Clinical Development
Irene brings more than 20 years of experience in clinical research and operations, and has led teams in support of the development of biopharma products and pharmaceutical first in class treatments in gene medicine, oncology, and infectious diseases.
HIV FUNCTIONAL CURE
Our globally recognized HIV functional cure team advises our researchers and participates in the successful administration of pre-clinical and expected clinical activities for AGT103-T HIV therapeutic. Read about our research.
Dr. John J. Rossi
City of Hope
Dr. Jose Bordon, MD, PhD, AAHIVS
Providence Hospital
IMMUNO-ONCOLOGY AND LIVER CANCER
Our proprietary lentiviral vectors deliver genetic medicines that have shown to both disable key drivers of tumor growth or immune evasion, and activate the body’s tumor immunity mechanisms for active cancer suppression. Our researchers collaborate with experts in cancer research and cell therapy to be a leader in immuno-oncology innovation. Read about our research.
CLINICAL TRIAL PARTNERS
Dr. Dean W. Felsher,
MD, PhD
Stanford University
School of Medicine
PHENYLKETONURIA (PKU)
Our researchers and collaborators are committed to finding a cure for PKU. We are developing and anticipate testing genetic medicines in humans in 2018 that may be used to treat or cure this life-threatening disease. Read about our research.
RESEARCH COLLABORATORS
Dr. Jerry Vockley, MD, PhD
University of Pittsburgh
School of Medicine
Dr. Steven Dobrowolski, PhD
University of Pittsburgh
School of Medicine
OTHER COLLABORATORS
Our proprietary lentiviral vectors deliver genetic medicines that have shown to both disable key drivers of tumor growth or immune evasion, and activate the body’s tumor immunity mechanisms for active cancer suppression. Our researchers collaborate with experts in cancer research and cell therapy to be a leader in immuno-oncology innovation. Read about our research.
Dr. Ted Dawson,
MD, PhD
Johns Hopkins
University
Dr. Robert Clarke,
Ph.D., D.Sc.
Georgetown University
Medical School
Dr. Fred Nyberg,
PhD
Uppsala University,
Sweden
BOARD OF DIRECTORS
Jeffrey A. Galvin
CEO and Founder
Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of…
Tommy Thompson
Director and Senior Advisor
Tommy Thompson, former Secretary of the United States Department of Health and Human Services, worked fervently to modernize healthcare delivery as the former Governor of…
Aaron Galvin
Director
Aaron Galvin earned his BS and MS from the Massachusetts Institute of Technology (MIT), joining the MIT Lincoln Labs to pioneer innovations to radar as well as developing technologies for various classified…
Qi Tang
Director
Qi Tang has developed manufacturing and import/export businesses throughout China and the United States, and has invested several times throughout AGT’s growth.
Julia Brown
Director
Julia Brown has served on the board of directors of nine drug development companies with a focus on governance and compensation. She currently serves on the board and as a member of the…
PROFESSIONAL ADVISORS
Snell & Wilmer strategically develops our intellectual property.
Foley & Lardner protects our innovative technologies and cures.
Cooley, LLP provides AGT with corporate legal advice.
Ernst & Young serves as our independent public accountant.
